Casirivimab-imdevimab (REGEN-COV)
What studies of Casirivimab-imdevimab (REGEN-COV) found
At a glance, by condition
Long COVID: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty): 9 findings, all C.
9 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Casirivimab-imdevimab (REGEN-COV) might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Casirivimab-imdevimab (REGEN-COV) · Long COVID is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Symptoms
Autonomic symptoms1 study · 3 (few people) people received Casirivimab-imdevimab (REGEN-COV) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (3 in all); not all results were tested against chance.
Studies with no comparison group3 in the study · minimally, for two years (few people)
Autonomic symptoms improved.
The evidence is very uncertain about the effect of casirivimab-imdevimab (REGEN-COV) on autonomic symptoms in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (3 in all)
- Not all results were tested against chance
See the 1 study
-
- People in the study
- 3 in the study
- Dose
- —
- Outcome
- Heart Racing/ Palpitations
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Breathlessness1 study · 3 (few people) people received Casirivimab-imdevimab (REGEN-COV) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (3 in all); not all results were tested against chance.
Studies with no comparison group3 in the study · minimally, for two years (few people)
Breathlessness improved.
The evidence is very uncertain about the effect of casirivimab-imdevimab (REGEN-COV) on breathlessness in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (3 in all)
- Not all results were tested against chance
See the 1 study
-
- People in the study
- 3 in the study
- Dose
- —
- Outcome
- Shortness of Breath
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Cognition (brain fog)1 study · 3 (few people) people received Casirivimab-imdevimab (REGEN-COV) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (3 in all); not all results were tested against chance.
Studies with no comparison group3 in the study · minimally, for two years (few people)
Cognition (brain fog) improved.
The evidence is very uncertain about the effect of casirivimab-imdevimab (REGEN-COV) on cognition (brain fog) in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (3 in all)
- Not all results were tested against chance
See the 1 study
-
- People in the study
- 3 in the study
- Dose
- —
- Outcome
- Brain Fog/Difficulty Concentrating
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Fatigue1 study · 3 (few people) people received Casirivimab-imdevimab (REGEN-COV) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (3 in all); not all results were tested against chance.
Studies with no comparison group3 in the study · minimally, for two years (few people)
Fatigue improved.
The evidence is very uncertain about the effect of casirivimab-imdevimab (REGEN-COV) on fatigue in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (3 in all)
- Not all results were tested against chance
See the 1 study
-
- People in the study
- 3 in the study
- Dose
- —
- Outcome
- Physical Fatigue (Lack of energy)
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Low mood or anxiety1 study · 3 (few people) people received Casirivimab-imdevimab (REGEN-COV) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (3 in all); not all results were tested against chance.
Studies with no comparison group3 in the study · minimally, for two years (few people)
Low mood or anxiety improved.
The evidence is very uncertain about the effect of casirivimab-imdevimab (REGEN-COV) on low mood or anxiety in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (3 in all)
- Not all results were tested against chance
See the 1 study
-
- People in the study
- 3 in the study
- Dose
- —
- Outcome
- Emotional Lability
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Pain1 study · 3 (few people) people received Casirivimab-imdevimab (REGEN-COV) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (3 in all); not all results were tested against chance.
Studies with no comparison group3 in the study · minimally, for two years (few people)
Pain improved.
The evidence is very uncertain about the effect of casirivimab-imdevimab (REGEN-COV) on pain in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (3 in all)
- Not all results were tested against chance
See the 1 study
-
- People in the study
- 3 in the study
- Dose
- —
- Outcome
- Joint Pain
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Sleep1 study · 3 (few people) people received Casirivimab-imdevimab (REGEN-COV) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (3 in all); not all results were tested against chance.
Studies with no comparison group3 in the study · minimally, for two years (few people)
Sleep improved.
The evidence is very uncertain about the effect of casirivimab-imdevimab (REGEN-COV) on sleep in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (3 in all)
- Not all results were tested against chance
See the 1 study
-
- People in the study
- 3 in the study
- Dose
- —
- Outcome
- Difficulty with Sleep/Unrestful Sleep
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Daily life and health overall
Daily functioning1 study · 3 (few people) people received Casirivimab-imdevimab (REGEN-COV) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (3 in all); not all results were tested against chance.
Studies with no comparison group3 in the study · minimally, for two years (few people)
Daily functioning improved.
The evidence is very uncertain about the effect of casirivimab-imdevimab (REGEN-COV) on daily functioning in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (3 in all)
- Not all results were tested against chance
See the 1 study
-
- People in the study
- 3 in the study
- Dose
- —
- Outcome
- Exercise Intolerance (Distance walked/ Ability to climb stairs)
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Overall symptoms1 study · 3 (few people) people received Casirivimab-imdevimab (REGEN-COV) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (3 in all); not all results were tested against chance.
Studies with no comparison group3 in the study · minimally, for two years (few people)
Overall symptoms improved.
The evidence is very uncertain about the effect of casirivimab-imdevimab (REGEN-COV) on overall symptoms in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (3 in all)
- Not all results were tested against chance
See the 1 study
-
- People in the study
- 3 in the study
- Dose
- —
- Outcome
- Total Score
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Side effects
Side effects studies reported1 kind
| Side effect | Studies that reported it |
|---|---|
| Worse symptoms or a flare | 1 study |